DOCSLIB.ORG

Optumrx Brand Pipeline Forecast

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

RxOutlook® 4th Quarter 2018 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2018 Possible launch date Zemcolo DNA-dependent RNA rifamycin Cosmo/ Dr. Falk Traveler's diarrhea PO Filed NDA 11/16/2018 N N (Aemcolo) polymerase inhibitor MNK-812 oxycodone Mallinckrodt opioid agonist Pain PO Filed NDA 11/16/2018 N N interferon-gamma Primary hemophagocytic NI-0501 emapalumab NovImmune SA IV Filed BLA 11/20/2018 Y Y antagonist lymphohistiocytosis Loxo Oncology/ LOXO-101 larotrectinib tyrosine kinase inhibitor Solid tumors/ Sarcoma PO Filed NDA 11/26/2018 Y Y Bayer Lambert-Eaton amifampridine potassium channel Firdapse BioMarin/ Catalyst myasthenic syndrome PO Filed NDA 11/28/2018 Y Y phosphate blocker (LEMS) Acute myelogenous ASP-2215 gilteritinib fumarate Astellas tyrosine kinase inhibitor PO Filed NDA 11/29/2018 Y Y leukemia bupivacaine XaraColl Innocoll sodium channel blocker Pain implant Filed NDA 12/2/2018 Y N implant gamma aminobutyric allopregnanolone acid-A (GABA-A) Postpartum depression/ SAGE-547 SAGE/ Ligand IV Filed NDA 12/19/2018 Y Y (brexanolone) receptor allosteric Seizures modulator optum.com/optumrx 1 RxOutlook® 4th Quarter 2018 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug ADX-N05 Jazz (ARL-N05, solriamfetol Pharmaceuticals/ phenylalanine derivative Narcolepsy/ Sleep apnea PO Filed NDA 12/20/2018 N Y JZP-110, SKL- Aerial BioPharma N05) SHP-555 prucalopride Shire 5-HT-4 receptor agonist Chronic constipation PO Filed NDA 12/21/2018 N N Acute lymphocytic EZN-2285 calaspargase pegol Shire enzyme therapy IM/IV Filed BLA 12/22/2018 Y N leukemia (ALL) Camurus/ opioid receptor agonist CAM-2038 buprenorphine Opioid dependence/ Pain SC Filed NDA 12/26/2018 Y N Braeburn (partial) dexamethasone Ocular Pain/ Allergic Dextenza corticosteroid implant Filed NDA 12/28/2018 N N sustained-release Therapeutix conjunctivitis Acute myeloid leukemia Cyclacel / Daiichi sapacitabine sapacitabine antimetabolite (AML)/ Non-small cell PO InTrial Late 2018 Y Y Sankyo lung cancer (NSCLC) growth hormone Helsinn / Novo Anorexia/ Cachexia FastTrk/ Adlumiz anamorelin secretagogue receptor PO Late 2018 Y N Nordisk (cancer-related) Breakthru (GHSR) agonist brincidofovir Adenovirus/ DNA-directed DNA FastTrk/ CMX-001 hexadecyloxypropy Chimerix Cytomegalovirus (CMV)/ PO Late 2018 N Y polymerase inhibitor Breakthru l ester Smallpox CEM-101 solithromycin Cempra macrolide Bacterial infections IV/PO CRL Late 2018 N N FastTrk/ BAY-41-6551 amikacin Nektar/ Bayer aminoglycoside Bacterial infections INH Late 2018 Y N Breakthru Kyowa Hakko A2A adenosine receptor Nouriast istradefylline Parkinson's disease PO CRL Late 2018 N N Kogyo/ Biovail antagonist protein absorption FastTrk/ CM-AT CM-AT Curemark Autism PO Late 2018 Y N enhancer Breakthru optum.com/optumrx 2 RxOutlook® 4th Quarter 2018 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug osmotic gradient Bronchitol mannitol Pharmaxis enhancer; mucus Asthma/ Cystic fibrosis INH InTrial Late 2018 N Y clearance enhancer combretastatin A4 phosphate vascular targeting agent Neuroendocrine tumors FastTrk/ Zybrestat OXiGENE IV Late 2018 Y Y (fosbretabulin (VTA) (NET)/ Glioma Breakthru tromethamine) pegylated arginine Hepacid ADI-PEG-20 Polaris Hepatic cancer IM InTrial Late 2018 Y Y deiminase Head and Neck cancer/ Ovarian cancer/ Fallopian IV/ FastTrk/ Reolysin pelareorep Oncolytics Biotech human reovirus Late 2018 Y Y tube cancer/ Peritoneal intratumoral Breakthru cancer/ Breast cancer beperminogene Peripheral artery disease AnGes / FastTrk/ Collategene perplasmid angiogenesis (PAD)/ Critical Limb IM Late 2018 Y N Mitsubishi Tanabe Breakthru (AMG-0001) Ischemia (CLI) serelaxin (RLX- recombinant human Reasanz Novartis Heart failure IV InTrial Late 2018 Y N 030) relaxin (rhRlx) agonist ITCA-650 glucagon-like peptide-1 (sustained exenatide Intarcia/ Quintiles/ (GLP-1) receptor Diabetes mellitus SC implant CRL Late 2018 Y N release sustained-release Servier agonist exenatide) Growth hormone somatropin somatropin Opko/ Pfizer enzyme replacement deficiency/ Small for SC InTrial Late 2018 Y Y gestational age (SGA) DCVax-L, glioblastoma Northwest vaccine Glioblastoma SC InTrial Late 2018 Y Y DCVax-Brain multiforme vaccine Biotherapeutics FastTrk/ NeuVax nelipepimut-S Galena vaccine Breast cancer intradermal Late 2018 Y N Breakthru optum.com/optumrx 3 RxOutlook® 4th Quarter 2018 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug Non-small cell lung tertomotide tertomotide (GV- KAEL-GemVax vaccine cancer (NSCLC)/ Intradermal InTrial Late 2018 Y N (GV-1001) 1001) Melanoma aldoxorubicin aldoxorubicin NantWorks/ CytRx anthracycline derivative Soft tissue sarcoma IV InTrial Late 2018 Y Y Xeglyze abametapir Hatchtech metalloprotease inhibitor Lice TOP CRL Late 2018 N N Fovista (E- Ophthotech/ antiplatelet derived Age-related macular FastTrk/ 10030; OAP- pegpleranib sodium Archemix/ growth factor subunit B Intravitreal Late 2018 Y N degeneration (AMD) Breakthru 030) Astellas/ Novartis (PDGF-B) aptamer Myelofibrosis (MF)/ Myelodysplastic Geron/ Johnson & FastTrk/ GRN-163L imetelstat telomerase inhibitor syndrome (MDS)/ Acute IV Late 2018 Y Y Johnson Breakthru myelogenous leukemia (AML) aldosterone synthase LCI-699 osilodrostat Novartis Cushing's syndrome PO InTrial Late 2018 N Y inhibitor opioid ELI-202 Elite opioid agonist Pain PO InTrial Late 2018 N N (undisclosed) long-acting beta 2 indacaterol/ adrenergic receptor glycopyrronium agonist (LABA)/ long- QVM-149 bromide/ Novartis/ Sosei Asthma INH InTrial Late 2018 N N acting muscarinic mometasone receptor antagonist furoate (LAMA)/ corticosteroid FMX-103 minocycline Foamix tetracyclines Rosacea TOP InTrial Late 2018 N N optum.com/optumrx 4 RxOutlook® 4th Quarter 2018 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug AM-111 (D- Xigen/ Auris JNK stress kinase Hearing loss/ Ocular Intratympanic/ FastTrk/ JNKI-1, XG- brimapitide Late 2018 Y Y Medical inhibitor inflammation Intraocular Breakthru 102) Diffuse large B-cell phosphoinositide-3 TG Therapeutics/ lymphoma (DLBCL)/ TGR-1202 umbralisib kinase (PI3K) delta PO InTrial Late 2018 Y Y Rhizen Chronic lymphocytic inhibitor leukemia (CLL) Spinocerebellar ataxia/ glutamate release FastTrk/ BHV-4157 trigriluzole Portage Biotech Obsessive-compulsive PO Late 2018 Y Y inhibitor Breakthru disorder (OCD) SEG-101 crizanlizumab Novartis P-selectin antagonist Sickle cell disease IV InTrial Late 2018 Y Y docosahexaenoic essential fatty acid SC-411 Sancilio Sickle cell disease (SCD) PO InTrial Late 2018 Y Y acid conjugate integrin receptor Ulcerative colitis (UC)/ Entyvio vedolizumab Takeda SC InTrial Late 2018 Y N antagonist Crohn's disease (CD) B-244 B-244 AOBiome antibacterial Acne TOP InTrial Late 2018 Y N phosphodiesterase-4 Otezla apremilast Celgene Psoriasis PO Filed sNDA Late 2018 Y N inhibitor Human lopinavir/ HIV-1 protease inhibitor/ Tentative lopinavir/ritonavir Cipla immunodeficiency virus PO Late 2018 Y N ritonavir CYP3A4 inhibitor Approval (HIV) tamsulosin tamsulosin Female Health/ alpha-adrenergic Benign prostatic PO Filed NDA Late 2018 N N DRS delayed-release Aspen antagonist hyperplasia (BPH) Acute myeloid leukemia PF-04449913 glasdegib maleate Pfizer hedgehog inhibitor PO Filed NDA Late 2018 Y Y (AML) tadalafil phosphodiesterase-5 tadalafil VersaFilm IntelGenx Erectile dysfunction PO Filed NDA Late 2018 Y N VersaFilm (PDE-5) inhibitor optum.com/optumrx 5 RxOutlook® 4th Quarter 2018 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug IntelGenx / Red VersaFilm rizatriptan triptans Acute migraines PO Filed NDA Late 2018 N N Hill Biopharma astodrimer sodium VivaGel Starpharma viral attachment inhibitor Bacterial infections VG Filed NDA Late 2018 N N (SPL-7013) nucleoside reverse tenofovir tenofovir disoproxyl transcriptase inhibitor disoproxyl Human fumarate/ (NRTI)/ NRTI/ non- Tentative fumarate/ Hetero Labs immunodeficiency virus PO Late 2018 Y N lamivudine/ nucleoside reverse Approval lamivudine/ (HIV) efavirenz transcriptase inhibitor efavirenz (NNRTI) nucleoside reverse tenofovir tenofovir disoproxyl transcriptase inhibitor disoproxyl Human fumarate/ (NRTI)/ NRTI/ non- Tentative fumarate/ Aurobindo immunodeficiency virus PO Late 2018 Y N lamivudine/ nucleoside reverse Approval lamivudine/ (HIV) efavirenz transcriptase inhibitor efavirenz (NNRTI) nucleoside reverse tenofovir tenofovir disoproxyl transcriptase inhibitor disoproxyl Human fumarate/ (NRTI)/ NRTI/ non- Tentative fumarate/ Cipla immunodeficiency virus PO Late 2018 Y N lamivudine/ nucleoside reverse Approval lamivudine/ (HIV) efavirenz transcriptase inhibitor efavirenz (NNRTI) nucleoside reverse tenofovir tenofovir disoproxyl transcriptase inhibitor disoproxyl Human fumarate/ (NRTI)/ NRTI/ non- Tentative fumarate/ Macleods immunodeficiency virus PO Late 2018 Y N lamivudine/ nucleoside reverse Approval lamivudine/ (HIV) efavirenz transcriptase inhibitor efavirenz (NNRTI) 2019 Possible launch date optum.com/optumrx 6 RxOutlook® 4th Quarter 2018
Recommended publications
  • Optumrx Brand Pipeline Forecast

    Optumrx Brand Pipeline Forecast

    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle

    Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle

    Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle Robert L Hendren, DO Professor of Psychiatry and Behavioral Science Idaho Autism Summit November 2, 2019 Faculty Disclosure • Grants — Curemark, Roche, Otsuka • Advisory Board — Curemark, BioMarin, Janssen, Axial Biotherapeutics • Honoraria/Royalties: Oxford University Press, Taylor & Francis • Dr. Hendren does intend to discuss the use of off- label/unapproved use of drugs Learning Objectives • Identify successes and challenges in the developmental progression through the life cycle for people with developmental disabilities and their families • Identify and effectively treat comorbid medical, emotional and behavioral symptoms associated with autism spectrum disorders (ASD) • Consider integrating biomedical treatments for ASD including conventional psychotropic medication and what has been referred to as CAM/CIM into a comprehensive program. 2010 1 in 68; 2014 1 in 59 CDC Prevalence of Autism • Possible explanations include – Diagnostic expansion and substitution – Better reporting – Increased recognition – Increasing acceptability – Immigration for services – Environmental toxins – Infectious and immune vulnerability – Epigenetic processes Rutter M. Acta Pediatr. 2005;94(1):2-15. Centers for Disease Control and Prevention. Autism Spectrum Disorders. www.cdc.gov/ncbddd/autism. Accessed June 16, 2015. Hagerman R, Hendren RL (Eds). Treatment of Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms. Oxford University Press; 2014. ASD Genetic Etiology (Levels 1 & 2) • Multiple genes: NRXN12q, 7q11.23, 15q11-13, 16p11.2, SHANK 3, 2, NLGN4, MTHFR 677>T, SEMA5A, 2Q22.1, GRIN2B, 5P14.1, CDH9, 10, FRX, PTEN • Identical twins: 60% to 90% – Fraternal twins: 0% to 36% – Siblings: 4% to 19% • Clear genetic etiology accounts for 25% of autism cases • Hundreds of genetic mutations, some de novo, lead to many ways to develop and treat autism • Is Precision Medicine Possible? Weiss KM, Issues Science and Technology in 2017 Levy D, et al.
  • Pharmacological Management of Autism Spectrum Disorders

    Pharmacological Management of Autism Spectrum Disorders

    Pharmacological Management of Autism Spectrum Disorders Lightin the Way 2018 David Ermer Md Pharmacotherapy common in Autism Spectrum iIlnesses (ASDs) ◼ 45% of children and adolescents with ASDs treated with psychotropic medications ◼ 75% of adults with ASDs treated with psychotropic medications Research into Psychotropic Medications in ASD’s is Relatively New ◼ Before 2006 there were no FDA approved medications for use in Autism ◼ With the increased incidence of ASDs being reported, there is increased interest from the pharmaceutical industry Treatment Strategies for Pharmacologic Intervention ◼ Pharmacologic treatments are available and significantly beneficial ◼ Educational and behavioral supports are the mainstays of treatment ◼ It is essential to integrate behavioral and pharmacologic treatments Realistic Expectations Must be Set ◼ Expectation that symptoms remit more quickly with pharmacologic treatment over behavioral treatments ◼ Expectation that response will be more complete with pharmacologic treatments ◼ “magic bullets” Must Optimize Environment ◼ Evaluate school setting ◼ Work with caregivers on home environment ◼ Pharmacologic strategies ineffective in unsupportive and inadequate environments Parental Collaboration is Essential ◼ Monitor patient and provide information to provider ◼ Administer medication ◼ Observe side effects ◼ Note emotional and behavioral effects ◼ Collaborate their information with school Focus on Symptom Clusters ◼ Most of the core symptoms are likely to remain ◼ Must focus on specific measurable symptoms
  • February 2021 EPS Pipeline Report

    February 2021 EPS Pipeline Report

    Pipeline Report February 2021 Pipeline Report February 2021 © 2021 Envolve. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs referenced in the following points. COVID-19 1 > Veklury is currently the only agent that is FDA-approved for the treatment of COVID-19. Three additional therapeutics and two vaccines have been granted Emergency Use Authorization (EUA), and at least three more vaccines are Recent Specialty Drug Approvals1 4 expected to receive an EUA in the relatively near future. > The previous quarter noted the approval of several breakthrough therapies for rare or ultra-rare conditions, which previously had no available FDA-approved Recent Non-Specialty Drug Approvals 9 treatments — Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies, Oxlumo for primary hyperoxaluria type 1, and Imcivree for genetically mediated obesity. Upcoming Specialty Products 10 > Other notable approvals include: Lupkynis — the first oral therapy approved for lupus nephritis; Orladeyo — the first oral therapy approved as prophylaxis of hereditary angioedema attacks;Cabenuva – the first long-acting injectable antiretroviral therapy intended as maintenance treatment of HIV; and Breyanzi — Upcoming Non-Specialty Products 18 the
  • CHMP Agenda of the 19-22 April 2021 Meeting

    CHMP Agenda of the 19-22 April 2021 Meeting

    28 July 2021 EMA/CHMP/220334/2021 Corr.11 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 19-22 April 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 19 April 2021, 09:00 – 19:30, virtual meeting/ room 1C 20 April 2021, 08:30 – 19:30, virtual meeting/ room 1C 21 April 2021, 08:30 – 19:30, virtual meeting/ room 1D 22 April 2021, 08:30 – 19:00, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). 1 Correction in section 8.1.1 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
  • Horizon Scanning Status Report, Volume 2

    Horizon Scanning Status Report, Volume 2

    PCORI Health Care Horizon Scanning System Volume 2, Issue 3 Horizon Scanning Status Report September 2020 Prepared for: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036 Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12 Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 Investigators: Randy Hulshizer, MA, MS Damian Carlson, MS Christian Cuevas, PhD Andrea Druga, PA-C Marcus Lynch, PhD, MBA Misha Mehta, MS Prital Patel, MPH Brian Wilkinson, MA Donna Beales, MLIS Jennifer De Lurio, MS Eloise DeHaan, BS Eileen Erinoff, MSLIS Cassia Hulshizer, AS Madison Kimball, MS Maria Middleton, MPH Diane Robertson, BA Melinda Rossi, BA Kelley Tipton, MPH Rosemary Walker, MLIS Andrew Furman, MD, MMM, FACEP Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the Horizon Scanning System has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions.
  • INN-Nimet 1 1.4.2019 a Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum Abagovomabi Abaloparatide Abaloparatidum Abalopara

    INN-Nimet 1 1.4.2019 a Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum Abagovomabi Abaloparatide Abaloparatidum Abalopara

    INN-nimet Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency 1.4.
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021

    Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021

    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
  • Networking Breakfast with ASBMR Leaders, NIH Representatives And

    Networking Breakfast with ASBMR Leaders, NIH Representatives And

    8/20/2019 ASBMR Connect: Networking Breakfast with ASBMR Leaders, NIH Representatives and Senior Investigators September 20, 2019, 06:45 AM W308/Orange County Convention Center ASBMR Connect is supported in part by educational grants from Amgen, Inc. and Ultragenyx Pharmaceutical Inc. The Networking Breakfast with ASBMR Leaders, NIH Representatives and Senior Investigators is a ticketed event that is part of the ASBMR Connect Program. ASBMR Connect requires advance registration and a separate ticket fee. Registration Open September 20, 2019, 07:00 AM Valencia Ballroom Lobby/Orange County Convention Center Gerald D. Aurbach Lecture and Presentation of Esteemed Awards September 20, 2019, 08:00 AM Valencia Ballroom B-D/Orange County Convention Center Join your colleagues to celebrate the following ASBMR 2019 Esteemed Award Winners: William F. Neuman Award, Paula Stern Achievement Award, Stephen M. Krane Award and Adele L. Boskey Award From Genes to Genomes to Biology and Health • Richard Lifton MD, PhD, Rockefeller University September 20, 08:30 AM-09:30 AM Valencia Ballroom B-D/Orange County Convention Center Networking Break September 20, 2019, 09:30 AM Valencia Foyer/Orange County Convention Center Highlights of the ASBMR 2019 Annual Meeting September 20, 2019, 10:00 AM Valencia Ballroom B-D/Orange County Convention Center • Dana Gaddy PhD, College of Veterinary Medicine, Texas A&M University, United States, Chair • Shonni Silverberg MD, Columbia University College of Physicians & Surgeons, United States, Chair • Johannes Van Leeuwen PhD, Erasmus University Medical Center, Netherlands, Chair This special session is of interest to all health professionals, first time meeting attendees, young investigators, individuals new to the field, nurses, clinical research study coordinators, physical therapists and/or those seeking guidance in navigating through the extensive ASBMR program.
  • PCORI-HCHSS-High Potential Disruption-May-2021

    PCORI-HCHSS-High Potential Disruption-May-2021

    PCORI Health Care Horizon Scanning System Volume 3 Issue 1 High Potential Disruption Report May 2021 Prepared for: Patient-Centered Outcomes Research Institute 1828 L St., NW, Suite 900 Washington, DC 20036 Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12 Prepared by: ECRI 5200 Butler Pike Plymouth Meeting, PA 19462 Investigators: Randy Hulshizer, MA, MS Jennifer De Lurio, MS Marcus Lynch, PhD, MBA Brian Wilkinson, MA Damian Carlson, MS Christian Cuevas, PhD Andrea Druga, MSPAS, PA-C Misha Mehta, MS Prital Patel, MPH Donna Beales, MLIS Eloise DeHaan, BS Eileen Erinoff, MSLIS Madison Kimball, MS Maria Middleton, MPH Melinda Rossi, BA Kelley Tipton, MPH Rosemary Walker, MLIS Andrew Furman, MD, MMM, FACEP Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG-2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions.
  • TAG Mail – 26 August 2021 COVID-19 RESOURCES & ARTICLES of INTEREST Please Click This Link for the Cumulative Listing of COVID-19 Resources in Past TAG Mails

    TAG Mail – 26 August 2021 COVID-19 RESOURCES & ARTICLES of INTEREST Please Click This Link for the Cumulative Listing of COVID-19 Resources in Past TAG Mails

    TAG Mail: July to December 2021 Cumulative Listing of Reports, Publications, Medication Safety TAG Mail – 26 August 2021 COVID-19 RESOURCES & ARTICLES OF INTEREST Please click this link for the cumulative listing of COVID-19 resources in past TAG Mails. AUSTRALIAN Agency for Clinical Innovation, NSW (ACI) - Caring for adults with COVID-10 in the community. Updated guide to care for adults with Delta variant - link Australian Government Department of Health - ATAGI update following weekly COVID-19 meeting 18 August 2021 - link - PHLN and CDNA joint statement on SARS-CoV-2 rapid antigen tests (updated 23/8/21) - link - Shared decision making guide to COVID-19 vaccination for women who are pregnant, breastfeeding or planning pregnancy - link, factsheets in English and other languages - COVID-19 National Health Plan: Prescriptions via telehealth. Guides for prescribers & pharmacists - ATAGI clinical guidance on COVID-19 vaccine in Australia in 2021 (updated 20/8/21) - link MJA Podcasts - Episode 33: COVID-19 in children National COVID-19 Clinical Evidence Taskforce - Taskforce makes new conditional recommendation for sotrovimab - link - New immunodulatory treatments comparison table - link - Tocilizumab and baricitinib FAQs - Ivermectin FAQs NSW Health - COVID-19 vaccination for workers - link - COVID-19 Weekly Surveillance in NSW - Epidemiological week 31, ending 7 August 2021 - link - Safety Notice 018/21: Myocarditis and pericarditis after mRNA COVID-19 vaccines - Statewide Protocol for the Supply or Administration of COVID-19 Vaccine. PD2021_032 (13/08/21) - New ‘find the facts’ webpage which provides data on COVID-19 cases, testing and vaccination and maps showing case numbers and vaccination rates based on location.